Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic...

Full description

Saved in:
Bibliographic Details
Published in:EBioMedicine 2017-12, Vol.26 (C), p.138-145
Main Authors: Krivoy, Amir, Onn, Roy, Vilner, Yael, Hochman, Eldar, Weizman, Shira, Paz, Amir, Hess, Shmuel, Sagy, Roi, Kimhi-Nesher, Shiri, Kalter, Ehud, Friedman, Tal, Friedman, Zvi, Bormant, Gil, Trommer, Sharon, Valevski, Avi, Weizman, Abraham
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Clozapine
Clozapine - administration & dosage
Clozapine - adverse effects
Cognition
Cognition - drug effects
Cognition - physiology
Dietary Supplements
Double-Blind Method
Female
Humans
Male
Metabolic syndrome
Metabolic Syndrome - blood
Metabolic Syndrome - diet therapy
Metabolic Syndrome - drug therapy
Metabolic Syndrome - pathology
Middle Aged
Mood
Psychotic Disorders - blood
Psychotic Disorders - diet therapy
Psychotic Disorders - drug therapy
Psychotic Disorders - pathology
Research Paper
Schizophrenia
Schizophrenia - blood
Schizophrenia - diet therapy
Schizophrenia - drug therapy
Schizophrenia - pathology
Vitamin D
Vitamin D - administration & dosage
Vitamin D - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963
cites cdi_FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963
container_end_page 145
container_issue C
container_start_page 138
container_title EBioMedicine
container_volume 26
creator Krivoy, Amir
Onn, Roy
Vilner, Yael
Hochman, Eldar
Weizman, Shira
Paz, Amir
Hess, Shmuel
Sagy, Roi
Kimhi-Nesher, Shiri
Kalter, Ehud
Friedman, Tal
Friedman, Zvi
Bormant, Gil
Trommer, Sharon
Valevski, Avi
Weizman, Abraham
description While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic parameters in chronic clozapine-treated schizophrenia patients. This eight-week, randomized, double-blind, placebo-controlled clinical trial, recruited schizophrenia patients who had been maintained on clozapine treatment for at least 18weeks and had low levels of vitamin D (70 (to ascertain the presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of vitamin D (14,000IU) or placebo and subsequently assessed at two-week intervals for psychosis severity, mood, cognition and metabolic profile. Twenty four patients were randomly assigned to vitamin D (aged 39.4±9.6years, 75% males) and the other 23 patients to the placebo arm (aged 42.5±11.2years, 60.9% males). After eight weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs −0.4nmol/l, p
doi_str_mv 10.1016/j.ebiom.2017.11.027
format article
fullrecord <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_944143d687cd49e69af5499f4226db81</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2352396417304711</els_id><doaj_id>oai_doaj_org_article_944143d687cd49e69af5499f4226db81</doaj_id><sourcerecordid>29226809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963</originalsourceid><addsrcrecordid>eNp9kd1u1DAQhSMEolXpEyAhPwAJ_ks2RgKpbPmpVImKFm6tsT1pvHLiyMkWsW_BG-N2oWpvuLI9M-cb-ZyieMloxShr3mwqND4OFadsVTFWUb56UhxyUfNSqEY-fXA_KI7neUMpZbXMxfZ5ccAV501L1WHx-4dfYPAjOSWX22kKOOC4wOLjSHJx3ac4eksube93ceoTjh7IRe7nqZlcJYQFHfnpl56sQ9zB5Ed8S07INxhdHPwO3WtyGrcmYPkh-DG_LgJYNLG0cVxSDCHL17njLYTM8xBeFM86CDMe_z2Piu-fPl6tv5TnXz-frU_OS1vzeilB0M4Y4xxzXEhhZY1oABCBClNLoI3BulNgnTJGNTWC63ClZCNMZzrViKPibM91ETZ6Sn6A9EtH8PquENO1hrR4G1ArKZkUrmlX1kmFjYKulkp1MrvoTMsy6_2eNW3NgM5mdxKER9DHndH3-jre6LoVvBEqA8QeYFOc54TdvZZRfRu43ui7wPVt4JoxnQPPqlcP195r_sWbB97tBzAbeeMx6dnm6Cw6n9Au-af-vwv-ACNXwhI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial</title><source>PubMed Central Free</source><source>Elsevier ScienceDirect Journals</source><creator>Krivoy, Amir ; Onn, Roy ; Vilner, Yael ; Hochman, Eldar ; Weizman, Shira ; Paz, Amir ; Hess, Shmuel ; Sagy, Roi ; Kimhi-Nesher, Shiri ; Kalter, Ehud ; Friedman, Tal ; Friedman, Zvi ; Bormant, Gil ; Trommer, Sharon ; Valevski, Avi ; Weizman, Abraham</creator><creatorcontrib>Krivoy, Amir ; Onn, Roy ; Vilner, Yael ; Hochman, Eldar ; Weizman, Shira ; Paz, Amir ; Hess, Shmuel ; Sagy, Roi ; Kimhi-Nesher, Shiri ; Kalter, Ehud ; Friedman, Tal ; Friedman, Zvi ; Bormant, Gil ; Trommer, Sharon ; Valevski, Avi ; Weizman, Abraham</creatorcontrib><description>While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic parameters in chronic clozapine-treated schizophrenia patients. This eight-week, randomized, double-blind, placebo-controlled clinical trial, recruited schizophrenia patients who had been maintained on clozapine treatment for at least 18weeks and had low levels of vitamin D (&lt;75nmol/l) and total PANSS scores &gt;70 (to ascertain the presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of vitamin D (14,000IU) or placebo and subsequently assessed at two-week intervals for psychosis severity, mood, cognition and metabolic profile. Twenty four patients were randomly assigned to vitamin D (aged 39.4±9.6years, 75% males) and the other 23 patients to the placebo arm (aged 42.5±11.2years, 60.9% males). After eight weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs −0.4nmol/l, p&lt;0.0001). There was no significant effect of vitamin D on psychotic, depressive or metabolic parameters. However, in the vitamin D group, there was a trend towards improved cognition (effect size=0.17, significance lost following Bonferroni correction). Vitamin D supplementation was associated with a trend towards improved cognition, but did not affect psychosis, mood or metabolic status. It is possible that the robust decrease in the PANSS scores in both groups may have obscured an effect of vitamin D supplementation. •This is the first study to explore the effects of vitamin D supplementation in chronic schizophrenia patients on clozapine•In this randomized double-blind study, patients received supplement vitamin D (14,000IU weekly) or placebo for eight weeks•There was no difference between vitamin D and placebo with regards to severity of psychopathology or metabolic status•There was a trend towards improved cognition following the effect of vitamin D specifically in attention and delayed recall About third of schizophrenia patients do not respond to common antipsychotics and require a clozapine trial. Insufficient levels of serum Vitamin D, the sunshine hormone, were found to be very prevalent among schizophrenia patients. The vitamin has a potent active metabolite with specific receptors in the brain. We investigated the psychiatric, metabolic and cognitive effects of vitamin D supplementation in comparison to placebo in clozapine-treated chronic schizophrenia patients with residual psychotic symptoms. Vitamin D addition was not superior to placebo in reducing psychiatric symptoms or improving the metabolic parameters. However, vitamin D administration was associated with a trend towards improvement in cognitive performance.</description><identifier>ISSN: 2352-3964</identifier><identifier>EISSN: 2352-3964</identifier><identifier>DOI: 10.1016/j.ebiom.2017.11.027</identifier><identifier>PMID: 29226809</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Antipsychotic Agents - administration &amp; dosage ; Antipsychotic Agents - adverse effects ; Clozapine ; Clozapine - administration &amp; dosage ; Clozapine - adverse effects ; Cognition ; Cognition - drug effects ; Cognition - physiology ; Dietary Supplements ; Double-Blind Method ; Female ; Humans ; Male ; Metabolic syndrome ; Metabolic Syndrome - blood ; Metabolic Syndrome - diet therapy ; Metabolic Syndrome - drug therapy ; Metabolic Syndrome - pathology ; Middle Aged ; Mood ; Psychotic Disorders - blood ; Psychotic Disorders - diet therapy ; Psychotic Disorders - drug therapy ; Psychotic Disorders - pathology ; Research Paper ; Schizophrenia ; Schizophrenia - blood ; Schizophrenia - diet therapy ; Schizophrenia - drug therapy ; Schizophrenia - pathology ; Vitamin D ; Vitamin D - administration &amp; dosage ; Vitamin D - blood</subject><ispartof>EBioMedicine, 2017-12, Vol.26 (C), p.138-145</ispartof><rights>2017 The Authors</rights><rights>Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.</rights><rights>2017 The Authors 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963</citedby><cites>FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963</cites><orcidid>0000-0003-2218-3250</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832639/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2352396417304711$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29226809$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krivoy, Amir</creatorcontrib><creatorcontrib>Onn, Roy</creatorcontrib><creatorcontrib>Vilner, Yael</creatorcontrib><creatorcontrib>Hochman, Eldar</creatorcontrib><creatorcontrib>Weizman, Shira</creatorcontrib><creatorcontrib>Paz, Amir</creatorcontrib><creatorcontrib>Hess, Shmuel</creatorcontrib><creatorcontrib>Sagy, Roi</creatorcontrib><creatorcontrib>Kimhi-Nesher, Shiri</creatorcontrib><creatorcontrib>Kalter, Ehud</creatorcontrib><creatorcontrib>Friedman, Tal</creatorcontrib><creatorcontrib>Friedman, Zvi</creatorcontrib><creatorcontrib>Bormant, Gil</creatorcontrib><creatorcontrib>Trommer, Sharon</creatorcontrib><creatorcontrib>Valevski, Avi</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><title>Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial</title><title>EBioMedicine</title><addtitle>EBioMedicine</addtitle><description>While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic parameters in chronic clozapine-treated schizophrenia patients. This eight-week, randomized, double-blind, placebo-controlled clinical trial, recruited schizophrenia patients who had been maintained on clozapine treatment for at least 18weeks and had low levels of vitamin D (&lt;75nmol/l) and total PANSS scores &gt;70 (to ascertain the presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of vitamin D (14,000IU) or placebo and subsequently assessed at two-week intervals for psychosis severity, mood, cognition and metabolic profile. Twenty four patients were randomly assigned to vitamin D (aged 39.4±9.6years, 75% males) and the other 23 patients to the placebo arm (aged 42.5±11.2years, 60.9% males). After eight weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs −0.4nmol/l, p&lt;0.0001). There was no significant effect of vitamin D on psychotic, depressive or metabolic parameters. However, in the vitamin D group, there was a trend towards improved cognition (effect size=0.17, significance lost following Bonferroni correction). Vitamin D supplementation was associated with a trend towards improved cognition, but did not affect psychosis, mood or metabolic status. It is possible that the robust decrease in the PANSS scores in both groups may have obscured an effect of vitamin D supplementation. •This is the first study to explore the effects of vitamin D supplementation in chronic schizophrenia patients on clozapine•In this randomized double-blind study, patients received supplement vitamin D (14,000IU weekly) or placebo for eight weeks•There was no difference between vitamin D and placebo with regards to severity of psychopathology or metabolic status•There was a trend towards improved cognition following the effect of vitamin D specifically in attention and delayed recall About third of schizophrenia patients do not respond to common antipsychotics and require a clozapine trial. Insufficient levels of serum Vitamin D, the sunshine hormone, were found to be very prevalent among schizophrenia patients. The vitamin has a potent active metabolite with specific receptors in the brain. We investigated the psychiatric, metabolic and cognitive effects of vitamin D supplementation in comparison to placebo in clozapine-treated chronic schizophrenia patients with residual psychotic symptoms. Vitamin D addition was not superior to placebo in reducing psychiatric symptoms or improving the metabolic parameters. However, vitamin D administration was associated with a trend towards improvement in cognitive performance.</description><subject>Adult</subject><subject>Antipsychotic Agents - administration &amp; dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Clozapine</subject><subject>Clozapine - administration &amp; dosage</subject><subject>Clozapine - adverse effects</subject><subject>Cognition</subject><subject>Cognition - drug effects</subject><subject>Cognition - physiology</subject><subject>Dietary Supplements</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - blood</subject><subject>Metabolic Syndrome - diet therapy</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Metabolic Syndrome - pathology</subject><subject>Middle Aged</subject><subject>Mood</subject><subject>Psychotic Disorders - blood</subject><subject>Psychotic Disorders - diet therapy</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - pathology</subject><subject>Research Paper</subject><subject>Schizophrenia</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - diet therapy</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - pathology</subject><subject>Vitamin D</subject><subject>Vitamin D - administration &amp; dosage</subject><subject>Vitamin D - blood</subject><issn>2352-3964</issn><issn>2352-3964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kd1u1DAQhSMEolXpEyAhPwAJ_ks2RgKpbPmpVImKFm6tsT1pvHLiyMkWsW_BG-N2oWpvuLI9M-cb-ZyieMloxShr3mwqND4OFadsVTFWUb56UhxyUfNSqEY-fXA_KI7neUMpZbXMxfZ5ccAV501L1WHx-4dfYPAjOSWX22kKOOC4wOLjSHJx3ac4eksube93ceoTjh7IRe7nqZlcJYQFHfnpl56sQ9zB5Ed8S07INxhdHPwO3WtyGrcmYPkh-DG_LgJYNLG0cVxSDCHL17njLYTM8xBeFM86CDMe_z2Piu-fPl6tv5TnXz-frU_OS1vzeilB0M4Y4xxzXEhhZY1oABCBClNLoI3BulNgnTJGNTWC63ClZCNMZzrViKPibM91ETZ6Sn6A9EtH8PquENO1hrR4G1ArKZkUrmlX1kmFjYKulkp1MrvoTMsy6_2eNW3NgM5mdxKER9DHndH3-jre6LoVvBEqA8QeYFOc54TdvZZRfRu43ui7wPVt4JoxnQPPqlcP195r_sWbB97tBzAbeeMx6dnm6Cw6n9Au-af-vwv-ACNXwhI</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Krivoy, Amir</creator><creator>Onn, Roy</creator><creator>Vilner, Yael</creator><creator>Hochman, Eldar</creator><creator>Weizman, Shira</creator><creator>Paz, Amir</creator><creator>Hess, Shmuel</creator><creator>Sagy, Roi</creator><creator>Kimhi-Nesher, Shiri</creator><creator>Kalter, Ehud</creator><creator>Friedman, Tal</creator><creator>Friedman, Zvi</creator><creator>Bormant, Gil</creator><creator>Trommer, Sharon</creator><creator>Valevski, Avi</creator><creator>Weizman, Abraham</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2218-3250</orcidid></search><sort><creationdate>20171201</creationdate><title>Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial</title><author>Krivoy, Amir ; Onn, Roy ; Vilner, Yael ; Hochman, Eldar ; Weizman, Shira ; Paz, Amir ; Hess, Shmuel ; Sagy, Roi ; Kimhi-Nesher, Shiri ; Kalter, Ehud ; Friedman, Tal ; Friedman, Zvi ; Bormant, Gil ; Trommer, Sharon ; Valevski, Avi ; Weizman, Abraham</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - administration &amp; dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Clozapine</topic><topic>Clozapine - administration &amp; dosage</topic><topic>Clozapine - adverse effects</topic><topic>Cognition</topic><topic>Cognition - drug effects</topic><topic>Cognition - physiology</topic><topic>Dietary Supplements</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - blood</topic><topic>Metabolic Syndrome - diet therapy</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Metabolic Syndrome - pathology</topic><topic>Middle Aged</topic><topic>Mood</topic><topic>Psychotic Disorders - blood</topic><topic>Psychotic Disorders - diet therapy</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - pathology</topic><topic>Research Paper</topic><topic>Schizophrenia</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - diet therapy</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - pathology</topic><topic>Vitamin D</topic><topic>Vitamin D - administration &amp; dosage</topic><topic>Vitamin D - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krivoy, Amir</creatorcontrib><creatorcontrib>Onn, Roy</creatorcontrib><creatorcontrib>Vilner, Yael</creatorcontrib><creatorcontrib>Hochman, Eldar</creatorcontrib><creatorcontrib>Weizman, Shira</creatorcontrib><creatorcontrib>Paz, Amir</creatorcontrib><creatorcontrib>Hess, Shmuel</creatorcontrib><creatorcontrib>Sagy, Roi</creatorcontrib><creatorcontrib>Kimhi-Nesher, Shiri</creatorcontrib><creatorcontrib>Kalter, Ehud</creatorcontrib><creatorcontrib>Friedman, Tal</creatorcontrib><creatorcontrib>Friedman, Zvi</creatorcontrib><creatorcontrib>Bormant, Gil</creatorcontrib><creatorcontrib>Trommer, Sharon</creatorcontrib><creatorcontrib>Valevski, Avi</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>EBioMedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krivoy, Amir</au><au>Onn, Roy</au><au>Vilner, Yael</au><au>Hochman, Eldar</au><au>Weizman, Shira</au><au>Paz, Amir</au><au>Hess, Shmuel</au><au>Sagy, Roi</au><au>Kimhi-Nesher, Shiri</au><au>Kalter, Ehud</au><au>Friedman, Tal</au><au>Friedman, Zvi</au><au>Bormant, Gil</au><au>Trommer, Sharon</au><au>Valevski, Avi</au><au>Weizman, Abraham</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial</atitle><jtitle>EBioMedicine</jtitle><addtitle>EBioMedicine</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>26</volume><issue>C</issue><spage>138</spage><epage>145</epage><pages>138-145</pages><issn>2352-3964</issn><eissn>2352-3964</eissn><abstract>While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic parameters in chronic clozapine-treated schizophrenia patients. This eight-week, randomized, double-blind, placebo-controlled clinical trial, recruited schizophrenia patients who had been maintained on clozapine treatment for at least 18weeks and had low levels of vitamin D (&lt;75nmol/l) and total PANSS scores &gt;70 (to ascertain the presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of vitamin D (14,000IU) or placebo and subsequently assessed at two-week intervals for psychosis severity, mood, cognition and metabolic profile. Twenty four patients were randomly assigned to vitamin D (aged 39.4±9.6years, 75% males) and the other 23 patients to the placebo arm (aged 42.5±11.2years, 60.9% males). After eight weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs −0.4nmol/l, p&lt;0.0001). There was no significant effect of vitamin D on psychotic, depressive or metabolic parameters. However, in the vitamin D group, there was a trend towards improved cognition (effect size=0.17, significance lost following Bonferroni correction). Vitamin D supplementation was associated with a trend towards improved cognition, but did not affect psychosis, mood or metabolic status. It is possible that the robust decrease in the PANSS scores in both groups may have obscured an effect of vitamin D supplementation. •This is the first study to explore the effects of vitamin D supplementation in chronic schizophrenia patients on clozapine•In this randomized double-blind study, patients received supplement vitamin D (14,000IU weekly) or placebo for eight weeks•There was no difference between vitamin D and placebo with regards to severity of psychopathology or metabolic status•There was a trend towards improved cognition following the effect of vitamin D specifically in attention and delayed recall About third of schizophrenia patients do not respond to common antipsychotics and require a clozapine trial. Insufficient levels of serum Vitamin D, the sunshine hormone, were found to be very prevalent among schizophrenia patients. The vitamin has a potent active metabolite with specific receptors in the brain. We investigated the psychiatric, metabolic and cognitive effects of vitamin D supplementation in comparison to placebo in clozapine-treated chronic schizophrenia patients with residual psychotic symptoms. Vitamin D addition was not superior to placebo in reducing psychiatric symptoms or improving the metabolic parameters. However, vitamin D administration was associated with a trend towards improvement in cognitive performance.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29226809</pmid><doi>10.1016/j.ebiom.2017.11.027</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2218-3250</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2352-3964
ispartof EBioMedicine, 2017-12, Vol.26 (C), p.138-145
issn 2352-3964
2352-3964
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_944143d687cd49e69af5499f4226db81
source PubMed Central Free; Elsevier ScienceDirect Journals
subjects Adult
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Clozapine
Clozapine - administration & dosage
Clozapine - adverse effects
Cognition
Cognition - drug effects
Cognition - physiology
Dietary Supplements
Double-Blind Method
Female
Humans
Male
Metabolic syndrome
Metabolic Syndrome - blood
Metabolic Syndrome - diet therapy
Metabolic Syndrome - drug therapy
Metabolic Syndrome - pathology
Middle Aged
Mood
Psychotic Disorders - blood
Psychotic Disorders - diet therapy
Psychotic Disorders - drug therapy
Psychotic Disorders - pathology
Research Paper
Schizophrenia
Schizophrenia - blood
Schizophrenia - diet therapy
Schizophrenia - drug therapy
Schizophrenia - pathology
Vitamin D
Vitamin D - administration & dosage
Vitamin D - blood
title Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A54%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D%20Supplementation%20in%20Chronic%20Schizophrenia%20Patients%20Treated%20with%20Clozapine:%20A%20Randomized,%20Double-Blind,%20Placebo-controlled%20Clinical%20Trial&rft.jtitle=EBioMedicine&rft.au=Krivoy,%20Amir&rft.date=2017-12-01&rft.volume=26&rft.issue=C&rft.spage=138&rft.epage=145&rft.pages=138-145&rft.issn=2352-3964&rft.eissn=2352-3964&rft_id=info:doi/10.1016/j.ebiom.2017.11.027&rft_dat=%3Cpubmed_doaj_%3E29226809%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-a30fbbbdd1d2343c45eebaaeea03b54a06be5f9acd9bb965eadfe79463bfbf963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29226809&rfr_iscdi=true